Dehaze, a Germany–based healthtech startup developing a foundational AI model for chronic disease detection, raised €3.2 million in a Seed funding round.
YZR Capital and DN Capital co-led the investment round with participation from Angel Invest, Zoho, and Better Ventures.
Dehaze plans to use the funds to expand its engineering and medical research teams and strengthen its foundational AI platform for early detection of chronic health risks.
DeHaze is developing a foundational AI model for chronic disease detection using causal AI trained on large-scale patient data. By emphasizing traceability, scalability, and clinical relevance, the platform helps providers and insurers identify high-risk individuals earlier, improving intervention outcomes and reducing healthcare costs.
Digital health companies, including healthcare AI startups, have secured more than $180 billion in funding to date, according to our recent Funding Database. More recently, Almanac Health, a provider of an AI-powered point-of-care evidence-based clinical decision support platform for healthcare providers, raised $10 million in Seed funding.
In another deal, SquareMind, a France-based robotics startup developing AI-powered dermatology solutions to make high-quality skin exams more efficient and accessible, raised $18 million in a pre-Series A funding round.